RET and medullary thyroid gland carcinoma: This drug was analyzed in a cohort of RET-mutated MTC patients in the phase I/II LIBRETTO-001 trial, achieving an ORR of 69% with a DCR of 95% in pretreated patients and an ORR of 73% with a DCR of 95% in treatment naïve patients [104].